DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on August 6, 2007; DOI: 10.1124/dmd.107.015883


0090-9556/07/3511-2053-2059$20.00
DMD 35:2053-2059, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.015883v1
35/11/2053    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walsky, R. L.
Right arrow Articles by Obach, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsky, R. L.
Right arrow Articles by Obach, R. S.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PHENCYCLIDINE
*THIO-TEPA

A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1',1''-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6

Robert L. Walsky, and R. Scott Obach

Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc., Groton, Connecticut

The use of selective chemical inhibitors of human cytochrome P450 (P450) enzymes represents a powerful method by which the relative contributions of various human P450 enzymes to the metabolism of drugs can be determined. However, the identification of CYP2B6 in the metabolism of drugs has been more challenging because of the lack of a well established inhibitor of this enzyme. In this report, we describe the selectivity of 2-phenyl-2-(1-piperidinyl)propane (PPP) as an inactivator of CYP2B6 and compare this selectivity versus other CYP2B6 inactivators: 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine. Values of KI and kinact for PPP were 5.6 µM and 0.13/min for bupropion hydroxylase catalyzed by pooled human liver microsomes, and values for thioTEPA were similar (4.8 µM and 0.20/min, respectively). Intrinsic inactivation capability was considerably greater for clopidogrel because of a greater kinact value (1.9/min). Ticlopidine was potent with KI and kinact values of 0.32 µM and 0.43/min, respectively. The selectivity of these four agents for CYP2B6 was determined by testing their effects on other human P450 enzyme activities using conditions that yield ~90% inactivation of CYP2B6 activity. The results showed that preincubation of human liver microsomes with PPP at 30 µM for 30 min provided more selective inhibition for CYP2B6 than thioTEPA, clopidogrel, and ticlopidine. Furthermore, the use of clopidogrel is complicated by the observation that this agent is not stable in the presence of human liver microsomes, even without addition of NADPH. Therefore, PPP can serve as a selective chemical inactivator of CYP2B6 and be used to define the role of CYP2B6 in the metabolism of drugs.


Address correspondence to: R. Scott Obach, Pfizer, Inc., Groton, CT 06340. E-mail: r.scott.obach{at}pfizer.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
M. Turpeinen, U. Hofmann, K. Klein, T. Murdter, M. Schwab, and U. M. Zanger
A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes
Drug Metab. Dispos., May 1, 2009; 37(5): 1017 - 1024.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
Y. Nishiya, K. Hagihara, T. Ito, M. Tajima, S.-i. Miura, A. Kurihara, N. A. Farid, and T. Ikeda
Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel
Drug Metab. Dispos., March 1, 2009; 37(3): 589 - 593.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. C. Talakad, S. Kumar, and J. R. Halpert
Decreased Susceptibility of the Cytochrome P450 2B6 Variant K262R to Inhibition by Several Clinically Important Drugs
Drug Metab. Dispos., March 1, 2009; 37(3): 644 - 650.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. K. Bae, S. Cao, K.-A. Seo, H. Kim, M.-J. Kim, J.-H. Shon, K.-H. Liu, H.-H. Zhou, and J.-G. Shin
Cytochrome P450 2B6 Catalyzes the Formation of Pharmacologically Active Sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) Metabolites in Human Liver Microsomes
Drug Metab. Dispos., August 1, 2008; 36(8): 1679 - 1688.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.